Show simple item record

dc.contributor.authorOkoli, Arinze Stanley
dc.contributor.authorOkeke, malachy ifeanyi
dc.contributor.authorTryland, Morten
dc.contributor.authorMoens, Ugo
dc.date.accessioned2018-05-08T11:39:25Z
dc.date.available2018-05-08T11:39:25Z
dc.date.issued2018-01-22
dc.description.abstract: The clustered regularly interspaced short palindromic repeat (CRISPR)/associated protein 9 (Cas9) technology is revolutionizing genome editing approaches. Its high efficiency, specificity, versatility, flexibility, simplicity and low cost have made the CRISPR/Cas9 system preferable to other guided site-specific nuclease-based systems such as TALENs (Transcription Activator-like Effector Nucleases) and ZFNs (Zinc Finger Nucleases) in genome editing of viruses. CRISPR/Cas9 is presently being applied in constructing viral mutants, preventing virus infections, eradicating proviral DNA, and inhibiting viral replication in infected cells. The successful adaptation of CRISPR/Cas9 to editing the genome of Vaccinia virus paves the way for its application in editing other vaccine/vector-relevant orthopoxvirus (OPXV) strains. Thus, CRISPR/Cas9 can be used to resolve some of the major hindrances to the development of OPXV-based recombinant vaccines and vectors, including sub-optimal immunogenicity; transgene and genome instability; reversion of attenuation; potential of spread of transgenes to wildtype strains and close contacts, which are important biosafety and risk assessment considerations. In this article, we review the published literature on the application of CRISPR/Cas9 in virus genome editing and discuss the potentials of CRISPR/Cas9 in advancing OPXV-based recombinant vaccines and vectors. We also discuss the application of CRISPR/Cas9 in combating viruses of clinical relevance, the limitations of CRISPR/Cas9 and the current strategies to overcome them.en_US
dc.descriptionSource at: <a href=http://doi.org/10.3390/v10010050> http://doi.org/10.3390/v10010050 </a>en_US
dc.identifier.citationOkoli, A. S., Okeke, M. I., Tryland, M. & Moens, U. (2018). CRISPR/Cas9—Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development. Viruses, 10(50), 1-27. http://doi.org/10.3390/v10010050en_US
dc.identifier.cristinIDFRIDAID 1551493
dc.identifier.doi10.3390/v10010050
dc.identifier.issn1999-4915
dc.identifier.urihttps://hdl.handle.net/10037/12710
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.journalViruses
dc.relation.projectIDForskningsrådet: ?en_US
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Matematikk og Naturvitenskap: 400::Zoologiske og botaniske fag: 480::Marinbiologi: 497en_US
dc.subjectVDP::Mathematics and natural science: 400::Zoology and botany: 480::Marine biology: 497en_US
dc.titleCRISPR/Cas9—Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Developmenten_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record